Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone

Giant Cell Tumor of Bone Clinical Trial

Official title:

A Phase Ib/II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of JMT103 in Surgically Unsalvageable or Refractory Giant Cell Tumor of Bone

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04255576
• Other study ID #: JMT103CN03
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: October 10, 2019
• Est. completion date: October 2023

Study information

• Verified date: October 2022
• Source: Shanghai JMT-Bio Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase Ib/II, multicenter, single-arm, open-label study to evaluate the efficacy and safety of JMT103 in patients with surgically unsalvageable or refractory giant cell tumor of bone (GCTB).

Description:

The objective of the trial is to evaluate the efficacy and safety of JMT103 in patients with GCTB that is surgically unsalvageable or for which the planned surgery is associated with severe morbidity. This study consists of two parts (phase Ib and II). In the phase Ib part, 6 to 12 subjects will be enrolled, and the safety, pharmacokinetics and pharmacodynamics of JMT103 will be evaluated after treatment for more than 4 weeks. And then the phase II part will be conducted, in which, 125 subjects will be enrolled. Eligible subjects will receive JMT103 at a dose of 2mg/kg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 2mg/kg SC on study days 8 and 15 until disease progression, tumor resection (the pathologic outcome after surgical resection is CR or PR), intolerable toxicity, decision by the participant to discontinue, or decision by the investigator that the subject could no longer benefit from the treatment (whichever occurs first).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 139
• Est. completion date: October 2023
• Est. primary completion date: September 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Fully informed and signed informed consent.

2. Male or female, Adults, 18 years and older

3. Histologically confirmed GCTB that is surgically unsalvageable or for which the planned surgery is associated with severe morbidity.

4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.

Exclusion Criteria:

1. Fertile subjects refuse to use effective contraception methods from the signing of the informed consent to 6 months after the last dose;

2. Active dental or jaw condition which requires oral surgery, including tooth extraction;

3. Currently receiving other anti-tumor therapy (radiotherapy, chemotherapy or arterial embolization, etc.);

4. Concurrent treatment with bisphosphonates;

5. Known history of second malignancy within the past 5 years, except for basal cell carcinoma or cervical carcinoma in situ.

Related Conditions & MeSH terms

• Bone Neoplasms
• Giant Cell Tumor of Bone
• Giant Cell Tumors

Intervention

Dietary Supplement:
• Dietary Supplement: Calcium/Vitamin D
All subjects should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of vitamin D), except in the case of pre-existing hypercalcemia.

Locations

Country	Name	City	State
China	Beijing Ji Shui Tan Hospital	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai JMT-Bio Inc.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants with Giant Cell Tumor Response	A treatment response was defined for participants with tissue samples obtained and measured by histopathology as: at least 90% elimination of giant cells relative to Baseline. A response was defined for participants who have only radiographs (histopathology not available) as lack of progression of the target lesion (PR or CR) at week 12 by radiographic measurements compared with Baseline.	From enrollment until 12 weeks
Secondary	Proportion of Participants with Adverse Events (AEs)		From enrollment until 90 days after the last dose
Secondary	Objective Response Rate (ORR)		From enrollment until the last dose, no more than 24 months
Secondary	Changes in Brief Pain Inventory Short Form (BPI-SF)	Assess pain and its effects on patients' mood, sleep, ability to move, appetite, daily life, ability to walk, and social interaction	From enrollment until the last dose, no more than 24 months
Secondary	Percentage of Patients with Surgical Resection of Tumor		From enrollment until the last dose, no more than 24 months
Secondary	Serum JMT103 Trough Concentrations		From enrollment until 90 days after the last dose
Secondary	Percent Change from Baseline in Serum C-terminus Peptide (of Type 1 Collagen) and Urinary N-telopeptide Corrected for Urine Creatinine		From enrollment until the last dose, no more than 24 months
Secondary	Number of Participants with Anti-JMT103 Antibodies		From enrollment until 90 days after the last dose
Secondary	Disease Control Rate (DCR)		From enrollment until the last dose, no more than 24 months
Secondary	Time to Progress (TTP)		From enrollment until the last dose, no more than 24 months